DissolutionExtendedReleaseQualityChecker

Dissolution Extended Release Quality Checker — Control of ER Product Dissolution

ℹ️  Utility checks dissolution profile compliance for modified-release forms:
   • Early time point: control of "dose dumping"
   • Middle time point: confirmation of release kinetics
   • Final time point: confirmation of completeness of release (usually >80-85%)

⚠️  CRITICAL: Exceeding the upper limit at the early point is life-threatening to the patient!
   Failure to reach the lower limit at the final point reduces therapeutic efficacy.

Usage:
 DissolutionExtendedReleaseQualityChecker.exe                            → demo mode (console output)
 DissolutionExtendedReleaseQualityChecker.exe input.csv output.json      → evaluate your data

Input format:
Batch,Time1,Diss1,Lower1,Upper1,Time2,Diss2,Lower2,Upper2,Time3,Diss3,Lower3,Upper3

Example:
 ER-TAB-2026-001,2,25.0,20.0,35.0,8,60.0,50.0,75.0,24,95.0,85.0,105.0

— WHY IS THIS NEEDED?
For extended-release products (ER, XR, SR, CR), the API release rate is critical.
• USP <724> and Ph. Eur. 2.9.3 require profile control at multiple time points.
• Early point (e.g., 1-2 h) ensures no toxic concentration peak.
• Middle point (e.g., 4-8 h) confirms the prolongation mechanism (diffusion, matrix erosion).
• Late point (e.g., 12-24 h) ensures the full dose is absorbed.
• Automation prevents manual comparison errors with specification tables.

⚠️  CRITICAL:
• Each of the three points must be within the specified range.
• Some methods also require calculation of similarity factor f2 against a reference profile.
• Test conditions (medium pH, apparatus type, rotation speed) must strictly follow the monograph.
• "Dose dumping" can be triggered by alcohol or pH changes, modeled in vitro.

Key features:
• Multi-point specification control.
• Detection of rapid dose release risks.
• Support for dissolution apparatus data (Apparatus 1/2/3/4).

Critical parameters:
• Early Point: Within [L-U]
• Middle Point: Within [L-U]
• Final Point: >= L

💡 Usage tips:
1. Use buffer solutions simulating GI conditions (pH 1.2, 4.5, 6.8).
2. For hydrophilic matrices, monitor medium viscosity.
3. Use biorelevant media (FaSSIF/FeSSIF) during development.
4. Compare profiles of different batches to monitor process stability.
5. If non-compliant, check tablet integrity (no mechanical damage).

⚠️ Note: Unlike immediate release, where only one point (Q) is important, for ER forms the shape of the dissolution curve is a Critical Quality Attribute (CQA) determining bioequivalence.